China Targets Widespread Brain-Computer Tech in 3-5 Years

Beijing Elevates BCIs to Core Strategic Industry

China has elevated brain-computer interfaces (BCIs) to the status of a core future strategic industry in its 15th Five-Year Plan, placing the technology alongside quantum computing, embodied AI, 6G, and nuclear fusion. The announcement came during China's annual parliamentary meetings in March 2026, signaling that Beijing views the technology as critical to its broader push for technological self-reliance.

Yao Dezhong, Director of the Sichuan Institute of Brain Science and a delegate to the National People's Congress, told reporters in Beijing on March 7 that China could see BCI products "moving towards actual practical service for the public" within three to five years as the technology matures and costs decrease.

China's BCI National Strategy

A national BCI development strategy released last year sets out a two-phase timeline. The first phase targets major technical breakthroughs by 2027, including establishing common industry standards and building a domestic supply chain. The second phase aims to cultivate two to three world-class BCI firms by 2030 capable of competing globally with companies like Neuralink.

The domestic BCI market is projected to reach 5.58 billion yuan ($809 million) by 2027, driven by clinical applications in rehabilitation, neurological disorders, and assistive technology. China's approach differs from the U.S. in scope: while American startups like Neuralink focus primarily on invasive chips that penetrate brain tissue, Chinese researchers are developing invasive, semi-invasive, and non-invasive BCI technologies with wider potential clinical use.

Over 10 Human Trials Already Underway

China is now the second country to launch invasive BCI human trials, with more than 10 active trials currently underway — matching the number in the United States. The country plans to enroll over 50 patients nationwide this year across various trial programs.

Recent clinical trials have demonstrated tangible results. Paralyzed patients and amputees have been able to regain partial mobility, operate robotic hands, and control intelligent wheelchairs using BCI technology developed in Chinese laboratories. These outcomes are drawing significant government attention and funding.

"After another three to five years, we will gradually see some BCI products moving towards actual practical service for the public." — Yao Dezhong, Director, Sichuan Institute of Brain Science

Racing to Match Neuralink

Regarding Neuralink's surgical robot capability, Yao acknowledged it as "a technical advantage, which I think is remarkable" but stated that "China is actually making very fast progress in this area now" and that "Musk's direction is basically achievable domestically."

China's competitive advantages in BCI development include its huge population with enormous patient demand, a cost-effective industrial chain, an abundant STEM talent pool, and growing government support through insurance integration and national standards. These structural factors could accelerate commercialization even if China trails the U.S. on certain technical frontiers.

What This Means for the Global Tech Industry

The elevation of BCIs to Five-Year Plan status signals that neurotechnology is entering the geopolitical competition between the U.S. and China, joining AI chips, quantum computing, and semiconductor manufacturing as strategic technology battlegrounds. For engineers and researchers working in neuroscience, hardware, and AI, this represents a significant expansion of government-backed funding and career opportunities on both sides of the Pacific.

The development also raises questions about regulatory frameworks for neurotechnology. As BCI devices move closer to consumer markets, issues around neural data privacy, cognitive liberty, and cross-border data governance will demand the same kind of international attention currently focused on AI regulation.